We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Patient-derived Organoid Model for Predicting the Chemoresponse in Patients With Colorectal Cancer.
- Authors
KIYOUN YI; SUNG HEE PARK; DONG UK KIM; DA YE JEON; HYE JI LEE; GEUN AM SONG; HONG JAE JO; DONG HOON BAEK; JEONG HEE HAN; BYOUNG CHUL LEE
- Abstract
Background/Aim: Cancer mortality has decreased due to the contribution of extensive research on cancer treatment, including chemotherapy, radiation, and immunotherapy. However, histopathologically similar tumors originating from the same organ are treated with identical or similar chemotherapeutic regimens regardless of patient characteristics or cancer subtypes. The aim of this study was to evaluate the utility of organoids in predicting responses to chemotherapeutic agents. Patients and Methods: This study retrospectively reviewed patient-derived organoids (PDOs) from 10 colorectal cancer patients to compare chemotherapy responses. Drug sensitivities for 5-fluorouracil (5-FU), cisplatin, oxaliplatin, and irinotecan were compared using GI50 (concentration that inhibits cancer cell growth by 50%). Results: When organoids were treated with 5-FU, GI50 was the lowest compared to the other three chemotherapeutic agents (cisplatin, oxaliplatin, and irinotecan). The responsiveness to chemotherapeutic agents differed depending on specific patient characteristics including age, tumor location, stage, and gross type. The response of the patients' organoids to chemotherapeutic agents was consistent with the response to chemotherapy actually performed in those patients with cancer recurrence after surgery. Conclusion: PDOs may be useful as a preclinical model in predicting chemotherapy responses in cancer patients.
- Subjects
COLORECTAL cancer; ORGANOIDS; CANCER-related mortality; CANCER treatment; FLUOROURACIL
- Publication
In Vivo, 2023, Vol 37, Issue 4, p1751
- ISSN
0258-851X
- Publication type
Article
- DOI
10.21873/invivo.13263